Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer
Journal of Clinical Oncology · 20.04.2026 · 44 (12) · 1139-1144
DOI: 10.1200/jco-25-01906 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.04.2026. Verfasst von Barbra A Dickerman und 2 weiteren Autor:innen. Beteiligte Einrichtung: CAUSALab, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA. Hauptthemen laut MEDLINE: Neoplasms, Clinical Decision-Making, Research Design, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Randomized trials provide evidence for regulatory and clinical decision making in oncology. However, trials cannot answer every important clinical question. Evidence gaps often persist in under-represented or small patient populations and for questions about head-to-head comparisons of active treatments, complex treatment strategies (including treatment sequencing and other dynamic treatment strategies), and long-term or rare outcomes. To address these questions, clinicians and researchers increasingly turn to observational (real-world) data. The target trial framework provides a systematic approach for designing observational analyses that attempt to emulate a hypothetical pragmatic trial. This process requires that investigators specify the key components of the causal question as elements of the target trial protocol: eligibility criteria, treatment strategies, assignment procedures, follow-up, outcomes, and causal contrasts. Explicitly emulating the target trial helps investigators avoid common study design flaws that can lead to immortal time and selection bias. Although the target trial framework helps to avoid such design-related biases, it cannot eliminate biases due to inherent data limitations, such as confounding and measurement error. Here we review target trial emulation to supplement evidence from randomized trials and inform regulatory and clinical decision making in oncology. Understanding the strengths and limitations of the target trial framework improves the integration of real-world evidence into modern cancer care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- CAUSALab, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA.
- RTI Health Solutions, Barcelona, Spain.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
ORCID-Profile: Xabier García-Albéniz, Miguel A Hernán
Zitieren
APA
Dickerman, B. A., García-Albéniz, X., & Hernán, M. A. (2026). Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer. Journal of Clinical Oncology, 44(12), 1139-1144. https://doi.org/10.1200/jco-25-01906
Vancouver
Dickerman BA, García-Albéniz X, Hernán MA. Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer. Journal of Clinical Oncology. 2026;44(12):1139-1144. doi:10.1200/jco-25-01906
BibTeX
@article{Dickerman2026,
author = {Dickerman, Barbra A and García-Albéniz, Xabier and Hernán, Miguel A},
title = {Target Trial Emulation for Regulatory and Clinical Decision Making in Cancer},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {12},
pages = {1139--1144},
doi = {10.1200/jco-25-01906}
}
EUVIMED